LDS/Medical Tests/Postmeiotic Segregation Increased 2 (PMS2) Gene Mutation Analysis

Postmeiotic Segregation Increased 2 (PMS2) Gene Mutation Analysis

The PMS2 gene is located in the short (p) arm of chromosome 7 at position 22.1 and encodes postmeiotic segregation increased 2 protein, a mismatch repair endonuclease enzyme. PMS2 protein plays an essential role to correct DNA mismatches and small insertions and deletions that can occur during DNA replication and homologous recombination. The PMS2 protein joins with another protein called MLH1 (produced from the MLH1 gene) to form a protein complex. This complex coordinates the activities of other proteins that repair errors made during DNA replication. Mutations in this gene have been associated with hereditary nonpolyposis colorectal cancer (HNPCC; also known as Lynch syndrome) and Turcot syndrome. PMS2 gene mutations involved in this condition lead to the production of an abnormally short or inactive PMS2 protein that cannot efficiently repair errors made during DNA replication. These errors accumulate as the cells continue to divide, increasing the risk of tumorigenesis.

Lynch syndrome is an autosomal dominantly inherited syndrome caused by germline mutations in one of the mismatch repair genes, MLH1, MSH2, MSH6, and PMS2. It is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. Heterozygous germline PMS2 mutations are found in about 2% of Lynch syndrome cases. The absence of PMS2 expression in tumors is due to silencing of remaining PMS2 gene by loss of heterozygosity. In addition to colorectal cancer, affected individuals may develop leukemia or lymphoma and may have light brown patches of skin called café-au-lait spots. Genetic testing can confirm the diagnosis of Lynch syndrome and can also identify presymptomatic individuals among the patient's relatives.

  • As an aid in diagnosis of Lynch syndrome/hereditary nonpolyposis colorectal cancer
  • To identify carrier of the familial PMS2 mutation by predictive testing in family members
  • For the prenatal genetic test in an individual at risk of Lynch syndrome
  • Any pathogenic variant or mutation in PMS2 gene is consistent with a diagnosis of Lynch syndrome.
  • Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
  • Appropriate screening procedures and/or prophylactic measures should be considered

Negative for mutations analyzed (No pathogenic variant or mutation detected)

By bidirectional sequence analysis of known variants, Next generation sequencing, PMS2 gene-targeted deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Array comparative genomic hybridization (aCGH), microsatellite instability testing, Lynch Syndrome panel test, BRAF V6OOE, MLH1 promoter hypermethylation, EPCAM mutations, MLH1gene mutation, MSH2 gene mutation, MSH6 gene mutation.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Genet. 2018;94:61-69. [PMID: 29286535]
  • Genes Chromosomes Cancer. 2013;52: 107-12. [PMID: 23012243]
  • Gastrointest Cancer Res. 2011;4: 188-90. [PMID: 22295133]
  • Gastroenterology. 2006;130: 312-22. [PMID: 16472587]
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/PMS2#
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1211/
  • Giardiello, F. M. Chapter 3; in Hereditary Colorectal Cancer and Polyp Syndromes. Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer, 2011: 21–30. doi:10.1016/b978-1-4160-4686-8.50008-7